A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Conditions

• Asthma

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Not accepted

Interventions

• PF-07275315 — DRUG
  subcutaneous injection
• Placebo — OTHER
  subcutaneous injection

Study Details

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over the last 12 months All participants will receive PF-07275315 or a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07275315 or placebo will be given as multiple shots in the clinic over the course of 12 weeks. We will compare the experiences of people receiving PF-07275315 to those of the people who do not. This will help us determine if PF-07275315 is safe and effective. Participants will be involved in this study for about 7.5 months. During this time, they will have 9 visits at the study clinic.

Key Dates

Start date

May 20, 2025

Status verified

Apr 2026

Primary completion

Mar 8, 2027

Completion

May 31, 2027

Study Design

Enrollment

252 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Treatment Arm A
  PF-07275315
• Experimental: Treatment Arm B
  PF-07275315
• Experimental: Treatment Arm C
  PF-07275315
• Placebo Comparator: Treatment Arm D
  Placebo

Primary Outcome Measure

Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12 [ Time Frame: Week 12 ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (36)

Find similar trials in Mobile, AL

Related Studies

• Personalized Environment and Genes Study
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Chapel Hill, North Carolina
• Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
  Recruiting · Gelb, Arthur F., M.D. · Lakewood, California
• Study of the Effect of Innate on the Inflammatory Response to Endotoxin
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
• Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
  PHASE4 · Recruiting · Gelb, Arthur F., M.D. · Lakewood, California